Navigation Links
Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
Date:10/25/2010

VIENNA, Oct. 25 /PRNewswire-FirstCall/ -- Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

In the randomized, controlled Phase II clinical trial (33 sites in 8 countries), about 400 mechanically ventilated intensive care patients, who are at particular high risk of acquiring severe and often life-threatening forms of Pseudomonas aeruginosa infections, such as Ventilator-Associated Pneumonia (VAP), sepsis or soft tissue infection were vaccinated on days zero and seven in four treatment groups  receiving 100 or 200mcg alum-adjuvanted vaccine, 100mcg non-adjuvanted vaccine or alum as placebo control.

The primary endpoint of the study was met in that all vaccine groups showed good seroconversion rates (65 - 81%) with IgG antibody Geometric Mean Titers (GMTs) (995-2117 ELISA units/ml). There were no significant differences in treatment emergent adverse events between the treatment arms and local and systemic tolerability appeared to be good, as far as assessable in this study population. The number and nature of reported drug related adverse events does not raise any safety concern and has been confirmed earlier by a Data Safety Monitoring Board (DSMB) based on interim data.

Secondary immunogenicity endpoints were also met in this study and included IgG response assessed seven times over a period of 90 days, measurement of functional antibody activity by opsonophagocytosis assay, and measurement of antibody avidity.

Overall robust immunogenicity following second vaccination was observed in all vaccine groups. A dose-response could be observed, whereas alum did not show a clear immune-enhancing effect. Antibody avid
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
2. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
3. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
4. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
5. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
6. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
7. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
8. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
9. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
10. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
11. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015   Royal Philips  (NYSE: ... Magnetic Resonance (MR) solutions to be showcased at the ... 23 rd Annual Meeting & Exhibition in ... Philips booth #301 will see the latest in ... increase clinical performance, enhance patient experience and provide economic ...
(Date:6/1/2015)... June 1, 2015 Novel t ... drive growth , says   GBI Research ... (NSCLC) treatment market will be driven primarily by the introduction ... treatment settings, which either replace or combine with generic chemotherapies. ... Non-Small Cell Lung Cancer Market to 2020 - ...
(Date:6/1/2015)... CEFALY Technology , the creators of ... authorized for use prior to the onset of migraine ... trial showing that the Cefaly device returns normal metabolic ... patients, namely the orbitofrontal cortex and rostral cingulate. ... an imaging test of the brain, used a radioactive substance called a ...
Breaking Medicine Technology:Philips showcases MR research solutions designed to enable collaboration with partners at the ISMRM Annual Meeting 2Philips showcases MR research solutions designed to enable collaboration with partners at the ISMRM Annual Meeting 3New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... TAINAN, Taiwan, Aug. 31 /PRNewswire-Asia/ -- ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ... for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { ...
Cached Medicine Technology:ScinoPharm to Invest in Tanvex Biologics 2ScinoPharm to Invest in Tanvex Biologics 3ScinoPharm to Invest in Tanvex Biologics 4ScinoPharm to Invest in Tanvex Biologics 5ScinoPharm to Invest in Tanvex Biologics 6PharmaVentures Appoints Paul Phull as Senior Director 2PharmaVentures Appoints Paul Phull as Senior Director 3PharmaVentures Appoints Paul Phull as Senior Director 4PharmaVentures Appoints Paul Phull as Senior Director 5PharmaVentures Appoints Paul Phull as Senior Director 6
(Date:6/1/2015)... 2015 "This milestone opens the doors ... previously able to buy and sell shares of our ... and also make recommendations to clients as they so ... to trade shares of our Company,” said Kris Finstad, ... requirements of OTCQB provides our investors greater confidence in ...
(Date:6/1/2015)... Pittsburgh, PA (PRWEB) June 01, 2015 ... this new development in breast cancer prevention. , A ... Health suggests that postmenopausal women with ductal carcinoma in ... cancer treatment and prevention. , The study (NSABP B-35/NRG ... those who completed the standard five-year treatment with tamoxifen ...
(Date:6/1/2015)... For years, facial plastic surgery demands ... like one would request a hairstyle, patients would use ... and more to illustrate their adaptation of choice. However, ... ushering in a new era of aesthetic envy – ... Rizk, MD, FACS notes that since the explosion of ...
(Date:6/1/2015)... There’s never a good time to be sick ... minor illnesses. , As of June 1, OSF HealthCare is ... care via the Internet. Patients throughout Illinois can access care ... “Everyone is busy. We know that getting in to see ... to make it easier,” said Jeffry Tillery, MD, Chief Transformation ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 June 1, ... of clinical journals in the areas of hospital medicine, ... announce that it has expanded upon its partnership with ... Hospital Medicine Practice, in a mobile application format ... tablets. , “We are very excited about the ...
Breaking Medicine News(10 mins):Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 3Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 4Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3
... Serena Gordon HealthDay Reporter , WEDNESDAY, May ... the drug lenalidomide can significantly lengthen the time that ... disease, either after having a stem cell transplant or ... studies is whether or not the improved "progression-free" survival ...
... today released a wide-ranging compendium of resources ... and secure sharing of health information. ... Policies in Practice for Health Information Sharingor ... for electronic health information sharing, including informed ...
... Infectious diseasesboth old and newcontinue to exact a devastating ... the world. Vaccines remain the best line of ... Stephen Johnston, researchers at Arizona State University,s Biodesign Institute, ... Texas Southwestern Medical Center are using clever functional screening ...
... -- The rate at which Americans are hospitalized for stroke ... According to the U.S. National Center for Health Statistics (NCHS), ... people during the 1990s but had decreased again to under ... there were still about 800,000 hospitalizations for stroke in 1989 ...
... support and limited pressure to achieve the ,thin and beautiful, ... a new study looking at five factors that may help ... the context of a society where discontent with appearance is ... the University of Arizona in the US, and colleagues is ...
... HealthDay Reporter , TUESDAY, May 8 (HealthDay News) ... atrial fibrillation face a 14 percent greater risk of ... report. The raised risk remained higher even when ... stroke, the study authors noted. "Previously, there was ...
Cached Medicine News:Health News:New Drug Shows Promise for Myeloma Patients 2Health News:New Drug Shows Promise for Myeloma Patients 3Health News:Markle releases new resources for health information sharing implementation 2Health News:Markle releases new resources for health information sharing implementation 3Health News:Advanced genetic screening method may speed vaccine development 2Health News:Advanced genetic screening method may speed vaccine development 3Health News:Advanced genetic screening method may speed vaccine development 4Health News:Rate of Hospitalizations for Stroke Has Declined in U.S. 2Health News:Self-worth needs to go beyond appearance 2Health News:Irregular Heartbeat Poses Greater Stroke Risk for Women Than Men 2
... and VersaStep™ PLUS Reposable system components for creating each ... radial expandable sleeve is packaged sterile together with either ... Insufflation and access needle is packaged non-sterile; 5 ... are packaged non-sterile; 5 mm, 7/8 mm, 10 ...
SURGISPIKE™ Single Use 5 mm Trocar. , ,Bladed Trocars are devices that contain a metal blade to gain access to the abdominal cavity....
... The complete line of Surgical Access ... ,The OnePort™ trocar system is actually ... be versatile, operationally flexible and clinically adaptive ... offering options in disposability and bladed or ...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
Medicine Products: